Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLEGRO-LT long-term ritlecitinib study in alopecia areata
2023-509801-59-00Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, open-label, single-arm trial of ritlecitinib tosilate in alopecia areata, sponsored by Pfizer. Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of serious adverse events and adverse events leading to discontinuation and 2 more. Started Jun 2024; status: completed.
02
Drugs
ritlecitinib tosilate
03
Conditions
alopecia areata
Beyond the preview
Go deeper on 2023-509801-59-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509801-59-00.